BioTech

Sweden's Cellink to buy U.S in-vitro company MatTek in $68 million deal

Swedish bioconvergence company Cellink has agreed to buy U.S.-based in-vitro technology firm MatTek for $68 million, Cellink said on Wednesday.

STOCKHOLM, March 10 (Reuters) - Swedish bioconvergence company Cellink CLNKb.ST has agreed to buy U.S.-based in-vitro technology firm MatTek for $68 million, Cellink said on Wednesday.

The company said it would pay 20% of the purchase price in newly issued B-shares and the rest in cash.

It said in a statement that by combining the two firms it would be able to offer market leading in-vitro methods and "finally replace controversial animal tests that are limited by their physiological relevance to predict human results".

Cellink, which develops technologies to culture cells in 3D, perform drug screening and print human tissues and organs, added that it was expecting the deal to close by March 24, provided that all conditions were met.

MatTek had revenues of $16.6 million in 2020.

(Reporting by Helena Soderpalm, editing by Anna Ringstrom)

((helena.soderpalm@thomsonreuters.com; +46 8 700 10 15; Reuters Messaging: helena.soderpalm.reuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

US Markets

Latest Technology Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More